Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides an overview of the Multiple Myeloma (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 10, 105, 118, 4, 10, 165, 29 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 19, 9, 32 and 8 molecules, respectively.

Multiple Myeloma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple Myeloma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple Myeloma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Multiple Myeloma (Kahler Disease) - Overview
Multiple Myeloma (Kahler Disease) - Therapeutics Development
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
Multiple Myeloma (Kahler Disease) - Drug Profiles
Multiple Myeloma (Kahler Disease) - Dormant Projects
Multiple Myeloma (Kahler Disease) - Discontinued Products
Multiple Myeloma (Kahler Disease) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Agenus Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Antengene Corp, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Multitude therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Starton Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Suzhou Maximum Bio-tech Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by T-CURX GmbH, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Oncology Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Triterpenoid Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Wugen Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by XNK Therapeutics AB, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Zhengda Tianqing Pharmaceutical Group Co Ltd, H1 2020
Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H1 2020
Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2020
Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2020
List of Figures
Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook